Oppenheimer Raises Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $48.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $46.00 to $48.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 7.50% from the stock’s previous close. […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Blackrock ,Dana Pizzuti ,Stephenf Betz ,Blackrock Inc ,Pricet Rowe Associates Inc ,Jennison Associates ,Crinetics Pharmaceuticals Price Performance ,Morgan Stanley ,Jefferies Financial Group ,Institutional Trading Of Crinetics Pharmaceuticals ,Analyst Recommendations For Crinetics Pharmaceuticals ,Wellington Management Group ,Securities Exchange Commission ,Crinetics Pharmaceuticals Inc ,Jpmorgan Chase Co ,Crinetics Pharmaceuticals ,Vanguard Group Inc ,Cantor Fitzgerald ,News Ratings For Crinetics Pharmaceuticals Daily ,Get Free Report ,Financial Group ,Exchange Commission ,Management Group ,Crinetics Pharmaceuticals Daily ,Nasdaq Crnx ,Crnx ,Medical ,Boost Price Target ,Oppenheimer Holdings Inc ,